Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimorazole or placebo with accelerated cisplatin chemoradiotherapy for hypoxic head and neck squamous cell carcinoma
NL-OMON45227Phase 3Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC), laryngeal squamous cell carcinoma (LSCC), squamous cell carcinoma of the hypopharynx and 1 more comparing Nimorazole + cisplatin chemoradiotherapy with Placebo + cisplatin chemoradiotherapy (2 arms). Started Dec 2014; status: active, not recruiting.
02
Drugs
nimorazole
03
Conditions
head and neck squamous cell carcinoma (HNSCC)laryngeal squamous cell carcinoma (LSCC)squamous cell carcinoma of the hypopharynxoropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NL-OMON45227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45227.